Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016.
作者信息
Dayoub Elias J, Nathan Ashwin S, Khatana Sameed Ahmed M, Seigerman Matthew, Tuteja Sony, Kobayashi Taisei, Kolansky Daniel M, Groeneveld Peter W, Giri Jay
机构信息
Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA (E.J.D., T.K., P.W.G., J.G.).
Center for Cardiovascular Outcomes, Quality, and Evaluative Research, University of Pennsylvania (E.J.D., A.S.N., S.A.M.K., T.K., P.W.G., J.G.).
出版信息
Circ Cardiovasc Interv. 2019 Jan;12(1):e007434. doi: 10.1161/CIRCINTERVENTIONS.118.007434.
Abstract
摘要
相似文献
1
Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016.
Circ Cardiovasc Interv. 2019 Jan;12(1):e007434. doi: 10.1161/CIRCINTERVENTIONS.118.007434.
2
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e006275. doi: 10.1161/CIRCOUTCOMES.119.006275. Epub 2020 Mar 11.
3
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
BMC Cardiovasc Disord. 2020 Mar 12;20(1):130. doi: 10.1186/s12872-020-01403-6.
4
Trends for and Clinical Factors Associated with Choice of Oral P2Y Inhibitors for Patients on Chronic Dialysis.
Cardiovasc Drugs Ther. 2019 Oct;33(5):511-521. doi: 10.1007/s10557-019-06913-w.
5
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
JACC Cardiovasc Interv. 2018 Aug 27;11(16):1576-1586. doi: 10.1016/j.jcin.2018.04.022. Epub 2018 May 24.
6
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].
G Ital Cardiol (Rome). 2020 Mar;21(3):171-174. doi: 10.1714/3306.32764.
7
Impact of Society Guidelines on Trends in Use of Newer P2Y Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
J Am Heart Assoc. 2024 May 7;13(9):e034414. doi: 10.1161/JAHA.124.034414. Epub 2024 May 3.
8
Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Curr Vasc Pharmacol. 2019;17(1):35-40. doi: 10.2174/1570161116666180206110657.
9
Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
Catheter Cardiovasc Interv. 2018 Oct 1;92(4):659-665. doi: 10.1002/ccd.27493. Epub 2018 Jan 22.
10
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Atherosclerosis. 2019 Feb;281:98-106. doi: 10.1016/j.atherosclerosis.2018.11.037. Epub 2018 Dec 7.
引用本文的文献
1
Temporal modulation (early escalation and late de-escalation) of antiplatelet therapy in patients undergoing complex high-risk PCI: rationale and design of the TAILORED-CHIP trial.
EuroIntervention. 2024 Nov 4;20(21):e1355-e1362. doi: 10.4244/EIJ-D-24-00437.
2
2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome.
Acta Cardiol Sin. 2023 Jan;39(1):4-96. doi: 10.6515/ACS.202301_39(1).20221103A.
3
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
EuroIntervention. 2023 Mar 20;18(15):1244-1253. doi: 10.4244/EIJ-D-22-00654.
4
A Japanese Dose of Prasugrel versus a Standard Dose of Clopidogrel in Patients with Acute Myocardial Infarction from the K-ACTIVE Registry.
J Clin Med. 2022 Apr 4;11(7):2016. doi: 10.3390/jcm11072016.
5
Identifying Racial, Ethnic, and Socioeconomic Inequities in the Use of Novel P2Y12 Inhibitors After Percutaneous Coronary Intervention.
J Invasive Cardiol. 2022 Mar;34(3):E171-E178. doi: 10.25270/jic/21.00055. Epub 2022 Jan 16.
6
Tai Chi Improves Coronary Heart Disease Risk by Inactivating MAPK/ERK Pathway through Serum miR-126.
Evid Based Complement Alternat Med. 2020 Apr 25;2020:4565438. doi: 10.1155/2020/4565438. eCollection 2020.
7
The 24-Form Tai Chi Improves Anxiety and Depression and Upregulates miR-17-92 in Coronary Heart Disease Patients After Percutaneous Coronary Intervention.
Front Physiol. 2020 Mar 11;11:149. doi: 10.3389/fphys.2020.00149. eCollection 2020.
8
Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.
JAMA Cardiol. 2020 Jan 1;5(1):21-29. doi: 10.1001/jamacardio.2019.4296.
9
Acute and 1-Year Hospitalization Costs for Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Results From the TRANSLATE-ACS Registry.
J Am Heart Assoc. 2019 Apr 16;8(8):e011322. doi: 10.1161/JAHA.118.011322.
本文引用的文献
1
Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease.
Circulation. 2018 Sep 25;138(13):1290-1300. doi: 10.1161/CIRCULATIONAHA.118.034790. Epub 2018 Jul 24.
2
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
JAMA Intern Med. 2018 Jul 1;178(7):943-950. doi: 10.1001/jamainternmed.2018.0783.
3
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.
Circulation. 2016 Sep 6;134(10):e123-55. doi: 10.1161/CIR.0000000000000404. Epub 2016 Mar 29.
4
Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need?
J Am Coll Cardiol. 2016 Feb 16;67(6):614-617. doi: 10.1016/j.jacc.2015.11.043.
Zotero 插件